EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia

Irene Kuriakose, Greg Noe, William Montgomery, Sahil Munjal

Psychopharmacology Bulletin · 2026

DOI: 10.64719/pb.16614 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Irene Kuriakose und 3 weiteren Autor:innen. Beteiligte Einrichtung: Kuriakose, BS, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia, Treatment-Resistant, Clozapine, Schizophrenia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a case of a 36-year-old female with schizophrenia, coronary artery disease, and type 2 diabetes who was hospitalized for altered mental status and persistent psychosis. Initial evaluation revealed myocardial infarction, pulmonary embolism, and urinary tract infection. While delirium resolved with treatment, psychotic symptoms persisted. Brain MRI showed diffuse cortical microhemorrhages, prompting extensive workup for vasculitis, infection, and prothrombotic syndromes, all of which were negative. Despite multiple antipsychotic trials (quetiapine, risperidone, ziprasidone), the patient remained symptomatic, with a PANSS score of 156, consistent with treatment-resistant schizophrenia (TRS). The patient was started on clozapine that was later augmented with electroconvulsive therapy (ECT). After 10 ECT sessions and clozapine titrated to 300 mg daily, her PANSS score improved significantly to 60. This case highlights the diagnostic complexity in medically ill psychiatric patients and the risk of delayed TRS diagnosis. Early use of standardized tools like PANSS in the general medical setting may be useful in differentiating psychiatric from medical causes and can expedite treatment. Though clozapine remains first-line for TRS, 45–70% may not respond to monotherapy.5,6,7 ECT augmentation was effective in our case, but evidence remains mixed,9 highlighting the need for further research into optimal TRS augmentation strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsSchizophrenia, Treatment-ResistantClozapineSchizophreniaHumansFemaleAdultDelayed DiagnosisElectroconvulsive Therapy

Stichwörter der Autor:innen

refractory schizophreniaschizophrenia and ECTschizophrenia and catatoniaschizophrenia and clozapineschizophrenic disorder

Substanzen

Antipsychotic AgentsClozapine

Autor:innen und Institutionen

  • Kuriakose, BS, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Noe, MD, Atrium Wake Forest Baptist Health, Psychiatry Residency Program, Winston-Salem, NC, USA.
  • Montgomery, MD, Atrium Wake Forest Baptist Health, Psychiatry Residency Program, Winston-Salem, NC, USA.
  • Munjal, MD, Department of Psychiatry, Wake Forest University School of Medicine, Winston Salem, NC, USA.

Zitieren

APA

Kuriakose, I., Noe, G., Montgomery, W., & Munjal, S. (2026). Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.16614

Vancouver

Kuriakose I, Noe G, Montgomery W, Munjal S. Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.16614

BibTeX
@article{Kuriakose2026,
  author = {Kuriakose, Irene and Noe, Greg and Montgomery, William and Munjal, Sahil},
  title = {Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  doi = {10.64719/pb.16614}
}
Kostenlos starten →